Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia [0.03%]
米哚妥林：一种针对FLT3突变急性髓系白血病的口服新药
Lindsay C Stansfield,Daniel A Pollyea
Lindsay C Stansfield
Acute myeloid leukemia (AML), a clonal hematologic malignancy that results in bone marrow failure, is the most common acute leukemia in adults (median age of diagnosis 67 yrs), and treatment options, especially in the elderly population, ar...
Trowels and Tribulations: Review of Antimicrobial-Impregnated Bone Cements in Prosthetic Joint Surgery [0.03%]
论柄与坎坷——人工关节置换手术中抗菌骨水泥评述
Vasilios Athans,Michael P Veve,Susan L Davis
Vasilios Athans
Antimicrobial-impregnated bone cement (AIBC) is a staple of contemporary orthopedic surgery and has been used to either treat or prevent prosthetic joint infection. Applied intraoperatively during primary arthroplasty or prosthetic joint ex...
A Comparison of Insulin Doses for the Treatment of Hyperkalemia in Patients with Renal Insufficiency [0.03%]
肾功能不全患者治疗高钾血症的胰岛素剂量比较研究
Heather A LaRue,Gary Daniel Peksa,Shital C Shah
Heather A LaRue
Study objective: To compare the safety and efficacy of 5 units versus 10 units of insulin for the treatment of hyperkalemia in patients with renal insufficiency. ...
Comparative Study
Pharmacotherapy. 2017 Dec;37(12):1516-1522. DOI:10.1002/phar.2038 2017
Renal Transplant Acute Rejection with Lower Mycophenolate Mofetil Dosing and Proton Pump Inhibitors or Histamine-2 Receptor Antagonists [0.03%]
他克莫司联合小剂量霉酚酸酯治疗肾移植受者的急性排斥反应
Kajal S Patel,Brian R Stephany,Julie F Barnes et al.
Kajal S Patel et al.
Background: Pharmacokinetic data show reduced mycophenolic acid levels in renal transplant recipients taking mycophenolate mofetil (MMF) and proton pump inhibitors (PPIs) concomitantly. This reduced exposure could increas...
Safety and Efficacy of Biologic Agents for the Management of Inflammatory Bowel Disease After Liver Transplantation [0.03%]
生物制剂治疗肝移植后炎症性肠病的安全性和有效性评估研究
Suhail A Shaikh,Linda Fitzgerald,Sarah Tischer
Suhail A Shaikh
Primary sclerosing cholangitis (PSC) frequently progresses to end-stage liver disease and cirrhosis, requiring liver transplantation. Approximately 70% of patients with PSC have concomitant inflammatory bowel disease (IBD) during their clin...
Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies [0.03%]
免疫检查点抑制剂癌症免疫疗法的免疫介导反应的药物流行病学评价
Ayad K Ali,David E Watson
Ayad K Ali
Study objective: Ipilimumab, pembrolizumab, and nivolumab are checkpoint inhibitors (CPIs) that activate T-cell-mediated immune response. CPI can provide durable benefits to some cancer patients with melanoma, renal cell ...
A Review of Immune Checkpoint Inhibitors for the Management of Locally Advanced or Metastatic Urothelial Carcinoma [0.03%]
免疫检查点抑制剂治疗局部晚期或转移性尿路上皮癌的疗效及安全性系统评价和 meta 分析
Kirollos S Hanna
Kirollos S Hanna
Urothelial carcinoma (UC) is the second most common malignancy of the genitourinary system and the sixth most common cancer in the United States. The overall incidence of UC appears to be on the decline, but death rates have remained stable...
Alternative Viewpoint: Predictors of Response in Emergency Department Patients Receiving Intravenous Opioids for Severe Pain [0.03%]
急诊应用静脉阿片类药物治疗重度疼痛患者的反应预测因素的另一种观点
James Priano,Brian Faley
James Priano
Alternative Viewpoint: Efficacy and Effectiveness of Respiratory Syncytial Virus Immunoprophylaxis in Children with Cystic Fibrosis - An Unsolved Question with More to Be Asked [0.03%]
另一种观点：囊性纤维化儿童呼吸道合胞病毒感染的免疫预防有效性问题有待进一步研究
Rees L Lee,Rebekah F Brown,Tebeb Gebretsadik et al.
Rees L Lee et al.
Influence of Kidney Transplant Status on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage [0.03%]
肾脏移植状态对华法林剂量、抗凝控制和出血风险的影响
Megan V Yanik,Marguerite R Irvin,T Mark Beasley et al.
Megan V Yanik et al.
Study design: To assess whether warfarin dose requirement, anticoagulation control, and risk of hemorrhage differ in kidney transplant recipients (KTRs) compared with patients without kidney transplants (non-KTRs). ...
Multicenter Study
Pharmacotherapy. 2017 Nov;37(11):1366-1373. DOI:10.1002/phar.2032 2017